Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction 
Company name: Dechra Veterinary Products Limited
Address: (A business unit of Dechra Pharmaceuticals PLC)
Sansaw Business Park
Hadnall, Shrewsbury
Shropshire SY4 4AS
Telephone: 01939 211200
Fax: 01939 211201
Email: info@dechra-uk.com
Website: www.dechra.com
Presentation
White, flat tablets with a bevelled edge and a break-line.
Each tablet contains:
Active substances: Paracetamol 400 mg
Codeine phosphate hemihydrate 9 mg
Uses
For analgesic therapy in the dog only. The product is indicated for acute pain of traumatic origin, as a complementary treatment in pain associated with other conditions, and post operative analgesia.
Dosage and administration
For oral administration.
1 tablet per 12 kg body weight every 8 hours.
Small dogs (up to 6 kg body weight): ½ tablet every 8 hours.
Medium dogs (6-18 kg body weight): ½-1½ tablets every 8 hours.
Large dogs (18-42 kg body weight): 1½-3½ tablets every 8 hours.
Treat for a maximum of 5 days.
Contraindications, warnings, etc
Do not exceed the stated dose or the duration of treatment.
Do not administer other NSAIDs concurrently or within 24 hours of each other.
Use is contraindicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastrointestinal ulceration or bleeding, or where there is evidence of blood dyscrasia or hypersensitivity to the product.
Do not use this preparation for cats.
Use in animals less than 6 weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management.
Avoid use in dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of increased renal toxicity.
Some NSAIDS may be highly bound to plasma proteins and compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations, which can lead to toxic effects.
Concurrent administration of potentially nephrotoxic drugs should be avoided.
There are no known contraindications for use during pregnancy.
If you notice any serious effects or other effects not mentioned in the data sheet, please inform your veterinary surgeon.
Overdose: Immediately seek the advice of a veterinary surgeon showing them the product literature.
Carry out lavage and treat with an intravenous injection of acetylcysteine (200 mg/ml) at a rate of 140 mg/kg every 6 hours for 7 treatments. Ascorbic acid (30 mg/kg) should also be given orally with each dose of acetylcysteine. If necessary, instigate fluid therapy using 'Ringers' or bicarbonate solution. Treat for codeine overdosing with intravenous injections of naloxone (1.0 mg/kg) repeated as necessary. Provide oxygen support.
Side effects: Occasional constipation due to codeine content.
Special precautions to be taken by the person administering the veterinary medicinal product to animals: Wash hands after use.
General precautions: For animal treatment only.
Keep out of the reach and sight of children.
Pharmaceutical precautions
Do not store above 25°C.
Do not use after the expiry date stated on the blister.
Disposal: Dispose of empty packaging and any remaining product in the household refuse.
Legal category
NFA-VPS
Packaging quantities
Containers of 100 and 500 tablets.
Further information
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infections, appropriate concurrent antimicrobial therapy should be instigated.
Seek veterinary advice if the treated condition does not improve or worsens during treatment.
UK authorised veterinary medicinal product.
Marketing authorisation holder (if different from distributor)
Dechra Limited, Dechra House, Jamage Industrial Estate, Talke Pits, Stoke-on-Trent, Staffordshire, ST7 1XW.
Marketing authorisation number
Vm 10434/4034.
| 
